JP2018502956A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502956A5
JP2018502956A5 JP2017533008A JP2017533008A JP2018502956A5 JP 2018502956 A5 JP2018502956 A5 JP 2018502956A5 JP 2017533008 A JP2017533008 A JP 2017533008A JP 2017533008 A JP2017533008 A JP 2017533008A JP 2018502956 A5 JP2018502956 A5 JP 2018502956A5
Authority
JP
Japan
Prior art keywords
copolymer
repeating units
composition
nucleic acid
repeating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502956A (ja
JP6745272B2 (ja
Filing date
Publication date
Priority claimed from EP14199439.2A external-priority patent/EP3034539A1/en
Application filed filed Critical
Publication of JP2018502956A publication Critical patent/JP2018502956A/ja
Publication of JP2018502956A5 publication Critical patent/JP2018502956A5/ja
Application granted granted Critical
Publication of JP6745272B2 publication Critical patent/JP6745272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533008A 2014-12-19 2015-12-18 核酸を細胞内へ導入するための組成物 Active JP6745272B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199439.2A EP3034539A1 (en) 2014-12-19 2014-12-19 Compositions for introducing nucleic acid into cells
EP14199439.2 2014-12-19
PCT/EP2015/080669 WO2016097377A1 (en) 2014-12-19 2015-12-18 Compositions for introducing nucleic acid into cells

Publications (3)

Publication Number Publication Date
JP2018502956A JP2018502956A (ja) 2018-02-01
JP2018502956A5 true JP2018502956A5 (enExample) 2019-02-07
JP6745272B2 JP6745272B2 (ja) 2020-08-26

Family

ID=52292658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533008A Active JP6745272B2 (ja) 2014-12-19 2015-12-18 核酸を細胞内へ導入するための組成物

Country Status (12)

Country Link
US (1) US11020487B2 (enExample)
EP (2) EP3034539A1 (enExample)
JP (1) JP6745272B2 (enExample)
KR (1) KR102142180B1 (enExample)
CN (1) CN107001627B (enExample)
AU (1) AU2015366220B2 (enExample)
BR (1) BR112017012482B1 (enExample)
CA (1) CA2971284C (enExample)
DK (1) DK3242903T3 (enExample)
ES (1) ES2887404T3 (enExample)
RU (1) RU2715227C2 (enExample)
WO (1) WO2016097377A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
GB2560250A (en) 2015-06-30 2018-09-05 Ethris Gmbh ATP-Binding cassette family coding polyribonucleotides and formulations thereof
WO2018010815A1 (en) * 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
KR20200109310A (ko) * 2018-01-11 2020-09-22 비온테크 알엔에이 파마슈티컬스 게엠베하 Rna의 투여를 위한 제형
US20210137840A1 (en) 2018-04-25 2021-05-13 Ethris Gmbh Lipid-based formulations for the delivery of rna
US20230000990A1 (en) * 2019-12-17 2023-01-05 Universiteit Gent Non-viral vectors comprising polypropyleneimine
CN111249476B (zh) * 2020-02-19 2023-09-26 深圳厚存纳米药业有限公司 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒
IL305353A (en) 2021-02-26 2023-10-01 Ethris Gmbh Formulations for aerosol formation and aerosols for the delivery of nucleic acid
WO2023049814A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index
CN118475371A (zh) * 2021-09-22 2024-08-09 圣诺制药公司 基于组氨酸-赖氨酸共聚物形成的改善的纳米颗粒制剂
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
WO2024240962A1 (en) 2023-05-25 2024-11-28 Ethris Gmbh Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
CN116478410B (zh) * 2023-06-20 2023-09-12 觅投克(北京)生物医学技术有限公司 一种菊糖修饰的聚乙烯亚胺衍生物及其制备方法和应用
CN121729225A (zh) 2023-08-25 2026-03-24 埃泽瑞斯公司 具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026082899A2 (en) 2024-10-16 2026-04-23 BioNTech SE Rna for preventing or treating tuberculosis

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
JPS5821590A (ja) 1981-07-31 1983-02-08 株式会社東芝 制御棒駆動水圧装置
JPS58215490A (ja) * 1982-06-08 1983-12-14 Nippon Shokubai Kagaku Kogyo Co Ltd 石炭−水スラリ−用分散剤
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
DE19527102A1 (de) * 1995-07-25 1997-01-30 Bayer Ag Neue Polyamine und ihre Verwendung in Lacken und Beschichtungen
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
EP1003527A4 (en) * 1997-08-01 2003-07-16 Supratek Pharma Inc POLYNUCLEOTIDE COMPOSITIONS
WO2001000708A1 (de) 1999-06-25 2001-01-04 Christian Plank Kombinationen zur einführung von nucleinsäuren in zellen
DE19933024C2 (de) 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Kationische Blockcopolymere
WO2002000870A2 (en) 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20070269891A9 (en) 2003-01-13 2007-11-22 Yasunobu Tanaka Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
US7829657B2 (en) 2005-02-10 2010-11-09 The University Of Tokyo Polycationically charged polymer and the use of the same as a carrier for nucleic acid
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
NZ569138A (en) 2005-12-15 2012-06-29 Centre Nat Rech Scient Cationic oligonucleotides automated methods for preparing same and their uses
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
GB0613753D0 (en) * 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
WO2009114854A1 (en) * 2008-03-14 2009-09-17 Egen, Inc. Biodegradable cross-linked branched poly (alkylene imines)
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2010065660A2 (en) 2008-12-02 2010-06-10 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery
CA2769670C (en) 2009-07-31 2018-10-02 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
WO2014025795A1 (en) 2012-08-07 2014-02-13 Northeastern University Compositions for the delivery of rna and drugs into cells
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells

Similar Documents

Publication Publication Date Title
JP2018502956A5 (enExample)
RU2017122022A (ru) Композиция для введения нуклеиновой кислоты в клетки
JP2018519835A5 (enExample)
HRP20200407T1 (hr) Terapeutske polimerne nanočestice i postupci dobivanja i korištenja istih
Guzman-Villanueva et al. Formulation approaches to short interfering RNA and MicroRNA: challenges and implications
JP2018110601A5 (enExample)
MX2013009191A (es) Oligonucleotidos antisentido.
JP2016517279A5 (enExample)
JP2019515908A5 (enExample)
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
JP2019511491A5 (enExample)
JP2014054250A5 (enExample)
JP2019516680A5 (enExample)
JP2016508134A5 (enExample)
PH12016500389A1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CY1118700T1 (el) Συνδυασμοι φαρμακων για τη θεραπευτικη αντιμετωπιση της μυϊκης δυστροφιας duchenne
JP2016517888A5 (enExample)
EP2308885A3 (en) Novel compounds and methods for therapy
JP2017141277A5 (enExample)
RU2015100198A (ru) Хиральный адъювант нуклеиновой кислоты
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP2013518107A5 (enExample)
RU2017121299A (ru) ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
JP2016521119A5 (enExample)
EA201070421A1 (ru) Микрорибонуклеиновые кислоты